254 related articles for article (PubMed ID: 22895060)
1. Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.
Huerta-Saquero A; Evangelista-Martínez Z; Moreno-Enriquez A; Perez-Rueda E
Bioengineered; 2013; 4(1):30-6. PubMed ID: 22895060
[TBL] [Abstract][Full Text] [Related]
2. Biochemical characterization of recombinant L-asparaginase (AnsA) from Rhizobium etli, a member of an increasing rhizobial-type family of L-asparaginases.
Moreno-Enriquez A; Evangelista-Martinez Z; Gonzalez-Mondragon EG; Calderon-Flores A; Arreguin R; Perez-Rueda E; Huerta-Saquero A
J Microbiol Biotechnol; 2012 Mar; 22(3):292-300. PubMed ID: 22450783
[TBL] [Abstract][Full Text] [Related]
3. A structural in silico analysis of the immunogenicity of l-asparaginase from Escherichia coli and Erwinia carotovora.
Belén LH; Lissabet JB; de Oliveira Rangel-Yagui C; Effer B; Monteiro G; Pessoa A; Farías Avendaño JG
Biologicals; 2019 May; 59():47-55. PubMed ID: 30871932
[TBL] [Abstract][Full Text] [Related]
4. Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases.
Pokrovsky VS; Kazanov MD; Dyakov IN; Pokrovskaya MV; Aleksandrova SS
BMC Cancer; 2016 Feb; 16():89. PubMed ID: 26867931
[TBL] [Abstract][Full Text] [Related]
5. Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?
Maese L; Rizzari C; Coleman R; Power A; van der Sluis I; Rau RE
Pediatr Blood Cancer; 2021 Oct; 68(10):e29169. PubMed ID: 34105243
[TBL] [Abstract][Full Text] [Related]
6. In silico identification and characterization of antineoplastic asparaginase enzyme from endophytic bacteria.
Zadeh Hosseingholi E; Neghabi N; Molavi G; Gheibi Hayat SM; Shahriarpour H
IUBMB Life; 2020 May; 72(5):991-1000. PubMed ID: 31981306
[TBL] [Abstract][Full Text] [Related]
7. Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
Figueiredo L; Cole PD; Drachtman RA
Expert Rev Hematol; 2016 Mar; 9(3):227-34. PubMed ID: 26765930
[TBL] [Abstract][Full Text] [Related]
8. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
[TBL] [Abstract][Full Text] [Related]
9. In Silico Design of a Chimeric Humanized L-asparaginase.
Pedroso A; Herrera Belén L; Beltrán JF; Castillo RL; Pessoa A; Pedroso E; Farías JG
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108713
[TBL] [Abstract][Full Text] [Related]
10. Decreasing the immunogenicity of Erwinia chrysanthemi asparaginase via protein engineering: computational approach.
Yari M; Eslami M; Ghoshoon MB; Nezafat N; Ghasemi Y
Mol Biol Rep; 2019 Oct; 46(5):4751-4761. PubMed ID: 31290058
[TBL] [Abstract][Full Text] [Related]
11. Crystal structures of the elusive Rhizobium etli L-asparaginase reveal a peculiar active site.
Loch JI; Imiolczyk B; Sliwiak J; Wantuch A; Bejger M; Gilski M; Jaskolski M
Nat Commun; 2021 Nov; 12(1):6717. PubMed ID: 34795296
[TBL] [Abstract][Full Text] [Related]
12. Design and Characterization of Erwinia Chrysanthemi l-Asparaginase Variants with Diminished l-Glutaminase Activity.
Nguyen HA; Su Y; Lavie A
J Biol Chem; 2016 Aug; 291(34):17664-76. PubMed ID: 27354283
[TBL] [Abstract][Full Text] [Related]
13. Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment.
Werner A; Röhm KH; Müller HJ
Biol Chem; 2005 Jun; 386(6):535-40. PubMed ID: 16006240
[TBL] [Abstract][Full Text] [Related]
14. Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase
Tong WH; Rizzari C
Haematologica; 2023 Oct; 108(10):2606-2615. PubMed ID: 37470157
[TBL] [Abstract][Full Text] [Related]
15. A Structural In Silico Analysis of the Immunogenicity of L-Asparaginase from
Andrade KCR; Homem-de-Mello M; Motta JA; Borges MG; de Abreu JAC; de Souza PM; Pessoa A; Pappas GJ; de Oliveira Magalhães P
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732010
[TBL] [Abstract][Full Text] [Related]
16. Quality comparison of a state-of-the-art preparation of a recombinant L-asparaginase derived from Escherichia coli with an alternative asparaginase product.
Schnuchel A; Radcke C; Theobald L; Doeding S
PLoS One; 2023; 18(6):e0285948. PubMed ID: 37319282
[TBL] [Abstract][Full Text] [Related]
17. Proteins from Erwinia asparaginase Erwinase ® and E. coli asparaginase 2 MEDAC ® for treatment of human leukemia, show a multitude of modifications for which the consequences are completely unclear.
Bae N; Pollak A; Lubec G
Electrophoresis; 2011 Jul; 32(14):1824-8. PubMed ID: 21769889
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of recent trends in research on therapeutically significant L-asparaginase and acute lymphoblastic leukemia.
Suresh SA; Ethiraj S; Rajnish KN
Mol Biol Rep; 2022 Dec; 49(12):11281-11287. PubMed ID: 35816224
[TBL] [Abstract][Full Text] [Related]
19. Asparaginase
Gao C; Ma X; Zhang Z; Lu Q; Ashby CR; Wei L; Chen ZS
Drugs Today (Barc); 2022 Jun; 58(6):261-271. PubMed ID: 35670704
[TBL] [Abstract][Full Text] [Related]
20. Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach.
Ramya LN; Pulicherla KK
Pathol Oncol Res; 2015 Sep; 21(4):909-20. PubMed ID: 25740072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]